Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications
- PMID: 1350941
- DOI: 10.1002/1097-0142(19920701)70:1+<254::aid-cncr2820701312>3.0.co;2-e
Neuroendocrine differentiation in carcinoma of the prostate. Diagnostic, prognostic, and therapeutic implications
Abstract
Endocrine-paracrine cells of the prostate (also known as APUD or neuroendocrine cells) constitute, in addition to the basal and exocrine secretory cells, a third population of highly specialized epithelial cells in the prostate gland. These endocrine-paracrine cells contain, and most likely secrete, serotonin and calcitonin, as well as variety of other peptides. Little is known of the functional role of these cells, but they probably subserve a paracrine or local regulatory role. They may also regulate via endocrine, lumencrine, or neurocrine mechanisms. These endocrine-paracrine cells probably play a significant role during prostatic growth and differentiation as well as regulating the secretory process of the mature gland. Neuroendocrine differentiation in prostatic carcinoma occurs in the form of the relatively rare small cell carcinoma and carcinoid or carcinoid-like tumor, but most commonly as focal neuroendocrine differentiation in a conventional prostatic adenocarcinoma that is a very frequent, if not ubiquitous phenomenon, and reflects tumor cell heterogeneity mimicking the normal differentiation process. The world's literature on neuroendocrine differentiation in prostatic carcinoma is reviewed. Neuroendocrine differentiation in all types of prostatic carcinoma appears to correlate with a poor prognosis. This correlation is probably multifactorial and may relate to a positive correlation with grade, a direct resistance to hormonal manipulation, and/or autocrine/paracrine growth factor activity due to the secretion of neuroendocrine products. Neuron-specific enolase and chromogranin, as well as other neuroendocrine products, may be useful as serum markers in patients with prostatic carcinoma with neuroendocrine differentiation. New therapeutic strategies need to be developed to treat these tumors. This includes the use of specialized protocols that have been effective against neuroendocrine carcinomas arising in other organ systems.
Similar articles
-
Neuroendocrine differentiation in human prostatic carcinoma.Hum Pathol. 1992 Mar;23(3):287-96. doi: 10.1016/0046-8177(92)90110-o. Hum Pathol. 1992. PMID: 1313390 Review.
-
The prostatic endocrine-paracrine (neuroendocrine) regulatory system and neuroendocrine differentiation in prostatic carcinoma: a review and future directions in basic research.J Urol. 1994 Nov;152(5 Pt 2):1927-31. doi: 10.1016/s0022-5347(17)32417-5. J Urol. 1994. PMID: 7933249 Review.
-
Neuroendocrine cells of the prostate and neuroendocrine differentiation in prostatic carcinoma: a review of morphologic aspects.Urology. 1998 May;51(5A Suppl):121-4. doi: 10.1016/s0090-4295(98)00064-8. Urology. 1998. PMID: 9610566 Review.
-
Neuroendocrine differentiation in prostatic malignancy.Cancer. 1996 Jul 15;78(2):357-61. doi: 10.1002/(SICI)1097-0142(19960715)78:2<357::AID-CNCR27>3.0.CO;2-U. Cancer. 1996. PMID: 8674017 Review.
-
Divergent neuroendocrine differentiation in prostatic carcinoma.Semin Diagn Pathol. 2000 May;17(2):149-61. Semin Diagn Pathol. 2000. PMID: 10839615 Review.
Cited by
-
Ectopic Cushing syndrome in metastatic castration‑resistant prostate cancer: A case report and review of literature.Oncol Lett. 2024 Jul 1;28(3):417. doi: 10.3892/ol.2024.14550. eCollection 2024 Sep. Oncol Lett. 2024. PMID: 39006947 Free PMC article.
-
Validation of SV2A-Targeted PET Imaging for Noninvasive Assessment of Neuroendocrine Differentiation in Prostate Cancer.Int J Mol Sci. 2021 Dec 3;22(23):13085. doi: 10.3390/ijms222313085. Int J Mol Sci. 2021. PMID: 34884893 Free PMC article.
-
Pure small cell carcinoma of the prostate: a case report and literature review.Case Rep Oncol. 2011 Feb 16;4(1):88-95. doi: 10.1159/000324717. Case Rep Oncol. 2011. PMID: 21475596 Free PMC article.
-
Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer.BMC Urol. 2008 Dec 30;8:21. doi: 10.1186/1471-2490-8-21. BMC Urol. 2008. PMID: 19115997 Free PMC article.
-
Precursor lesions for prostate cancer.J R Soc Med. 1997 Oct;90(10):533-9. doi: 10.1177/014107689709001003. J R Soc Med. 1997. PMID: 9488009 Free PMC article. Review. No abstract available.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical